FDA approves MET inhibitor Tabrecta for metastatic non-small cell lung cancer with METex14 skipping mutation.- Novartis
Novartis announced that the FDA approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a… read more.